Search Results - "GOSS, Glenwood"

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

“…Summary Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor…”
Get full text

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial by Soria, Jean-Charles, Prof, Felip, Enriqueta, MD, Cobo, Manuel, MD, Lu, Shun, MD, Syrigos, Konstantinos, Prof, Lee, Ki Hyeong, MD, Göker, Erdem, MD, Georgoulias, Vassilis, Prof, Li, Wei, MD, Isla, Dolores, MD, Guclu, Salih Z, MD, Morabito, Alessandro, MD, Min, Young J, MD, Ardizzoni, Andrea, MD, Gadgeel, Shirish M, Prof, Wang, Bushi, PhD, Chand, Vikram K, MD, Goss, Glenwood D, Prof

“…Summary Background There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an…”
Get full text

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer by Carrier, Marc, Abou-Nassar, Karim, Mallick, Ranjeeta, Tagalakis, Vicky, Shivakumar, Sudeep, Schattner, Ariah, Kuruvilla, Philip, Hill, Danny, Spadafora, Silvana, Marquis, Katerine, Trinkaus, Mateya, Tomiak, Anna, Lee, Agnes Y.Y, Gross, Peter L, Lazo-Langner, Alejandro, El-Maraghi, Robert, Goss, Glenwood, Le Gal, Gregoire, Stewart, David, Ramsay, Timothy, Rodger, Marc, Witham, Debra, Wells, Philip S

“…Patients receiving cancer treatment who had an intermediate-to-high risk of venous thromboembolism were randomly assigned to apixaban or placebo for 6 months…”
Get full text

Probability of Cancer in Pulmonary Nodules Detected on First Screening CT by McWilliams, Annette, Tammemagi, Martin C, Mayo, John R, Roberts, Heidi, Liu, Geoffrey, Soghrati, Kam, Yasufuku, Kazuhiro, Martel, Simon, Laberge, Francis, Gingras, Michel, Atkar-Khattra, Sukhinder, Berg, Christine D, Evans, Ken, Finley, Richard, Yee, John, English, John, Nasute, Paola, Goffin, John, Puksa, Serge, Stewart, Lori, Tsai, Scott, Johnston, Michael R, Manos, Daria, Nicholas, Garth, Goss, Glenwood D, Seely, Jean M, Amjadi, Kayvan, Tremblay, Alain, Burrowes, Paul, MacEachern, Paul, Bhatia, Rick, Tsao, Ming-Sound, Lam, Stephen

“…Using data from two large data sets of lung-cancer screening by CT, the authors identified factors that increased the likelihood that a nodule was malignant,…”
Get full text

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer by Laurie, Scott A, Goss, Glenwood D

“…Worldwide, the majority of patients with advanced non-small-cell lung cancer (NSCLC) do not have activating mutations in the tyrosine kinase domain of the…”
Get full text

Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study by GOSS, Glenwood D, O'CALLAGHAN, Chris, PISTERS, Katherine, GANDARA, David, KERNSTINE, Kemp, BUTTS, Charles, NOBLE, Jonathan, HENSING, Thomas A, ROWLAND, Kendrith, SCHILLER, Joan, KEYUE DING, SHEPHERD, Frances A, LORIMER, Ian, TSAO, Ming-Sound, MASTERS, Gregory A, JETT, James, EDELMAN, Martin J, LILENBAUM, Rogerio, CHOY, Hak, KHURI, Fadlo

“…Survival of patients with completely resected non-small-cell lung cancer (NSCLC) is unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not…”
Get full text

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer by Jenkins, Suzanne, Yang, James C-H, Ramalingam, Suresh S, Yu, Karen, Patel, Sabina, Weston, Susie, Hodge, Rachel, Cantarini, Mireille, Jänne, Pasi A, Mitsudomi, Tetsuya, Goss, Glenwood D

“…Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive, costly, and not always feasible for patients with late-stage disease. The clinical…”
Get more information

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer by NATALE, Ronald B, THONGPRASERT, Sumitra, BARLESI, Fabrice, LANGMUIR, Peter, GOGOV, Sven, ROWBOTTOM, Jacqui A, GOSS, Glenwood D, GRECO, F. Anthony, THOMAS, Michael, TSAI, Chun-Ming, SUNPAWERAVONG, Patrapim, FERRY, David, MULATERO, Clive, WHORF, Robert, THOMPSON, Joyce

“…Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This phase III study…”
Get full text

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial by Ellis, Peter M, Dr, Shepherd, Frances A, Prof, Millward, Michael, Prof, Perrone, Francesco, PhD, Seymour, Lesley, Prof, Liu, Geoffrey, MD, Sun, Sophie, MD, Cho, Byoung Chul, MD, Morabito, Alessandro, MD, Leighl, Natasha B, MD, Stockler, Martin R, Prof, Lee, Christopher W, MD, Wierzbicki, Rafal, MD, Cohen, Victor, MD, Blais, Normand, MSc, Sangha, Randeep S, MD, Favaretto, Adolfo G, MD, Kang, Jin Hyoung, MD, Tsao, Ming-Sound, Prof, Wilson, Carolyn F, MSc, Goldberg, Zelanna, MD, Ding, Keyue, PhD, Goss, Glenwood D, Prof, Bradbury, Penelope Ann, MBBCh

“…Summary Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung…”
Get full text

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer by Andrews Wright, Natalie M., Goss, Glenwood D.

“…Mutations in the epidermal growth factor receptor ( EGFR ) gene are the most common targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring…”
Get full text

Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3 by Weberpals, Johanne I, Lo, Bryan, Duciaume, Marc M, Spaans, Johanna N, Clancy, Aisling A, Dimitroulakos, Jim, Goss, Glenwood D, Sekhon, Harman S

“…Patients with advanced or recurrent invasive vulvar squamous cell carcinoma (VSCC) have limited treatment options and a grave prognosis. Understanding the…”
Get full text

Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study by Tammemagi, Martin C, Schmidt, Heidi, Martel, Simon, McWilliams, Annette, Goffin, John R, Johnston, Michael R, Nicholas, Garth, Tremblay, Alain, Bhatia, Rick, Liu, Geoffrey, Soghrati, Kam, Yasufuku, Kazuhiro, Hwang, David M, Laberge, Francis, Gingras, Michel, Pasian, Sergio, Couture, Christian, Mayo, John R, Nasute Fauerbach, Paola V, Atkar-Khattra, Sukhinder, Peacock, Stuart J, Cressman, Sonya, Ionescu, Diana, English, John C, Finley, Richard J, Yee, John, Puksa, Serge, Stewart, Lori, Tsai, Scott, Haider, Ehsan, Boylan, Colm, Cutz, Jean-Claude, Manos, Daria, Xu, Zhaolin, Goss, Glenwood D, Seely, Jean M, Amjadi, Kayvan, Sekhon, Harmanjatinder S, Burrowes, Paul, MacEachern, Paul, Urbanski, Stefan, Sin, Don D, Tan, Wan C, Leighl, Natasha B, Shepherd, Frances A, Evans, William K, Tsao, Ming-Sound, Lam, Stephen

“…Results from retrospective studies indicate that selecting individuals for low-dose CT lung cancer screening on the basis of a highly predictive risk model is…”
Get full text

Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung by Goss, Glenwood D., Spaans, Johanna N.

“…Molecular therapies targeting epidermal growth factor receptor (EGFR) have had a profound impact on the management of advanced non‐small cell lung cancer…”
Get full text

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer by Howe, Grant A, Xiao, Bin, Zhao, Huijun, Al-Zahrani, Khalid N, Hasim, Mohamed S, Villeneuve, James, Sekhon, Harmanjatinder S, Goss, Glenwood D, Sabourin, Luc A, Dimitroulakos, Jim, Addison, Christina L

“…Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with…”
Get full text

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer by Spaans, Johanna N, Goss, Glenwood D

“…Our ability to detect and directly target the oncogenic alterations responsible for tumor proliferation has contributed significantly to the management of lung…”
Get full text

Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials by Asmis, Timothy R, Ding, Keyue, Seymour, Lesley, Shepherd, Frances A, Leighl, Natasha B, Winton, Tim L, Whitehead, Marlo, Spaans, Johanna N, Graham, Barbara C, Goss, Glenwood D

“…This study analyzed patients enrolled in two large, prospectively randomized trials of systemic chemotherapy (adjuvant/palliative setting) for non-small-cell…”
Get full text

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study by GOSS, Glenwood D, ARNOLD, Andrew, ELLIS, Peter M, LAURIE, Scott A, DING, Keyue, FRYMIRE, Eliot, GAUTHIER, Isabelle, LEIGHL, Natasha B, HO, Cheryl, NOBLE, Jonathan, LEE, Christopher W, SEYMOUR, Lesley, SHEPHERD, Frances A, DEDIU, Mircea, CIULEANU, Tudor-Eliade, FENTON, David, ZUKIN, Mauro, WALDE, David, LABERGE, Francis, VINCENT, Mark D

“…PURPOSE This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced…”
Get full text

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10 by BUTTS, Charles A, KEYUE DING, CORMIER, Yvon, GOSS, Glenwood, FINDLAY, Brian, JOHNSTON, Michael, TSAO, Ming-Sound, SHEPHERD, Frances A, SEYMOUR, Lesley, TWUMASI-ANKRAH, Philip, GRAHAM, Barbara, GANDARA, David, JOHNSON, David H, KESLER, Kenneth A, GREEN, Mark, VINCENT, Mark

“…PURPOSE Adjuvant cisplatin-based chemotherapy (ACT) is now an accepted standard for completely resected stage II and III A non-small-cell lung cancer (NSCLC)…”
Get full text

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC by Leighl, Natasha B, Laurie, Scott A, Goss, Glenwood D, Hughes, Brett G M, Stockler, Martin, Tsao, Ming-Sound, Hwang, David M, Joubert, Phillipe, Kulkarni, Swati, Blais, Normand, Joy, Anil A, Mates, Mihaela, Rana, Punam, Yadav, Sunil K, Underhill, Craig, Lee, Christopher, Bradbury, Penelope A, Hiltz, Andrea, Dancey, Janet, Ding, Keyue, Vera-Badillo, Francisco

“…First-line therapy for patients with metastatic NSCLC includes checkpoint inhibitor monotherapy, dual checkpoint inhibition, or combination with chemotherapy…”
Get more information

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor by Goss, Glenwood D., Vokes, Everett E., Gordon, Michael S., Gandhi, Leena, Papadopoulos, Kyriakos P., Rasco, Drew W., Fischer, JuDee S., Chu, Katharine L., Ames, William W., Mittapalli, Rajendar K., Lee, Ho‐Jin, Zeng, Jiewei, Roberts‐Rapp, Lisa A., Loberg, Lise I., Ansell, Peter J., Reilly, Edward B., Ocampo, Christopher J., Holen, Kyle D., Tolcher, Anthony W.

“…BACKGROUND Epidermal growth factor receptor (EGFR) alterations are associated with multiple cancers. Current EGFR‐directed therapies have led to increased…”
Get full text